Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance.
A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial / Han, Changsu; Wang, Sheng-Min; Bahk, Won-Myong; Lee, Soo-Jung; Patkar, Ashwin A; Masand, Prakash S; Mandelli, Laura; Pae, Chi-Un; Serretti, Alessandro. - In: CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE. - ISSN 1738-1088. - STAMPA. - 16:4(2018), pp. 469-480. [10.9758/cpn.2018.16.4.469]
A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
Mandelli, Laura;Serretti, Alessandro
2018
Abstract
Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
